DEVELOPMENT OF MYELO001 AS AN ORALLY APPLIED MEDICAL COUNTERMEASURE FOR THE TREATMENT OF HEMATOPOIETIC ACUTE RADIATION SYNDROME

Myelo Therapeutics Gmbh, Berlin

Investigators

Abstract

The Contract was awarded to evaluate and develop a medical countermeasure for the treatment of Human Acute Radiation Syndrome (H-ARS) 24 hours post radiation.